Home » Market News » DirectorsTalk Highlights » Open Orphan aims to develop study model for Covid-19 vaccines
Open Orphan PLC

Open Orphan aims to develop study model for Covid-19 vaccines

Dublin-listed Open Orphan is currently developing the world’s first challenge study model to test the effectiveness of Covid-19 vaccines that are in development.

These types of studies have the potential to streamline and/or accelerate vaccine development.

Since it added the two companies to its stable, Open Orphan has made cost savings of €2m in Hvivo and €3m in Venn, according to annual results from the group.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.